StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.62 | $3.91 | +8.01% | 0.2M |
| 05-12 | $3.82 | $3.12 | -18.32% | 0.2M |
| 05-13 | $2.90 | $3.06 | +5.52% | 0.1M |
| 05-14 | $3.05 | $3.09 | +1.31% | 0.0M |
| 05-15 | $3.02 | $2.93 | -2.98% | 0.1M |
Each factor shows KALA's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for KALA.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q3 2026 (Est.) Expected 2026-08-06 | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|---|
Revenue | Not available | $0.00 | $0.00 | $0.00 | $3.89M |
Operating Income | Not available | $-39.16M | $-40.98M | $-39.66M | $-81.71M |
Net Income | Not available | $-26.98M | $-38.51M | $-42.20M | $-44.82M |
EPS (Diluted) | $-0.30 | $-3.31 | $-10.15 | $-17.35 | $-29.48 |
Total Assets | Not available | $9.49M | $55.48M | $55.95M | $86.82M |
Total Liabilities | Not available | $2.49M | $43.15M | $48.45M | $67.85M |
Cash & Equivalents | Not available | $7.56M | $51.18M | $50.90M | $70.50M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 557.00K | 6.09M | 2.76M | 1.71M |
Fundamentals not available for KALA.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.